Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
issued a press release announcing its financial results for the
first quarter ended March 31, 2017. A copy of this press release
is attached hereto as Exhibit 99.1.
attached hereto, is being furnished and shall not be deemed to be
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liability of that section, nor shall it be deemed
incorporated by reference into any of the Registrants filings
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
a filing to this Current Report on Form 8-K.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release dated May 8, 2017.
|
About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Recent Trading Information
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) closed its last trading session down -0.87 at 12.31 with 458,644 shares trading hands.
